Citigroup
KYTX icon

Citigroup’s Kyverna Therapeutics KYTX Stock Holding History

Citigroup’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$365K Buy
42,260
+29,963
+244% +$250K ﹤0.01% 3718
2025
Q4 		$116K Buy
12,297
+8,978
+271% +$66.7K ﹤0.01% 4263
2025
Q3 		$19.9K Sell
3,319
-12,513
-79% -$50K ﹤0.01% 4821
2025
Q2 		$48.6K Sell
15,832
-3,321
-17% -$8.21K ﹤0.01% 4771
2025
Q1 		$37K Sell
19,153
-1,172
-6% -$3.46K ﹤0.01% 4961
2024
Q4 		$76K Buy
20,325
+6,831
+51% +$32.7K ﹤0.01% 4950
2024
Q3 		$66K Buy
13,494
+8,318
+161% +$64.1K ﹤0.01% 4929
2024
Q2 		$38.8K Sell
5,176
-54,490
-91% -$832K ﹤0.01% 4723
2024
Q1 		$1.48M Buy
+59,666
New +$1.66M ﹤0.01% 2698

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Citigroup's KYTX Position: Q1 2026 in Review

Citigroup increased its Kyverna Therapeutics (KYTX) stake by 244% in Q1 2026, buying an estimated $250K and bringing the position to 42,260 shares worth $365K. The position accounts for ﹤0.01% of the portfolio, ranked #3718.

Citigroup first reported a position in KYTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $1.48M in Q1 2024. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Citigroup held 42,260 shares of Kyverna Therapeutics worth $365K as of Q1 2026.
  • Citigroup bought 29,963 Kyverna Therapeutics shares in Q1 2026, an estimated $250K.
  • Kyverna Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3718 holding.
  • Citigroup first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • Citigroup's Kyverna Therapeutics position peaked at $1.48M in Q1 2024.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.